(en) Gulamhusein S, Ko P, Carruthers SG et al., « Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil », Circulation, vol. 65, no 2, , p. 348–54. (PMID7053894, DOI10.1161/01.cir.65.2.348, lire en ligne)
doi.org
dx.doi.org
(en) Borowiec AM, Właszczuk A, Olakowska E, Lewin-Kowalik J., « TXNIP inhibition in the treatment of diabetes: verapamil as a novel therapeutic modality in diabetic patients », Med Pharm Rep, vol. 95, no 3, , p. 243-50. (PMID36060506, PMCIDPMC9387585, DOI10.15386/mpr-2187, lire en ligne)
(en) McVean J, Forlenza GP, Beck RW et al., « Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial », JAMA, vol. 329, no 12, , :980-99. (PMID36826834, PMCIDPMC9960023, DOI10.1001/jama.2023.2063, lire en ligne)
(en) Lundstrom T, Ryden L, « Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil », J Am Coll Cardiol, vol. 16, no 1, , p. 86–90. (PMID2358610, DOI10.1016/0735-1097(90)90461-w, lire en ligne)
(en) Gulamhusein S, Ko P, Carruthers SG et al., « Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil », Circulation, vol. 65, no 2, , p. 348–54. (PMID7053894, DOI10.1161/01.cir.65.2.348, lire en ligne)
jamanetwork.com
(en) McVean J, Forlenza GP, Beck RW et al., « Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial », JAMA, vol. 329, no 12, , :980-99. (PMID36826834, PMCIDPMC9960023, DOI10.1001/jama.2023.2063, lire en ligne)
medpharmareports.com
(en) Borowiec AM, Właszczuk A, Olakowska E, Lewin-Kowalik J., « TXNIP inhibition in the treatment of diabetes: verapamil as a novel therapeutic modality in diabetic patients », Med Pharm Rep, vol. 95, no 3, , p. 243-50. (PMID36060506, PMCIDPMC9387585, DOI10.15386/mpr-2187, lire en ligne)
(en) Borowiec AM, Właszczuk A, Olakowska E, Lewin-Kowalik J., « TXNIP inhibition in the treatment of diabetes: verapamil as a novel therapeutic modality in diabetic patients », Med Pharm Rep, vol. 95, no 3, , p. 243-50. (PMID36060506, PMCIDPMC9387585, DOI10.15386/mpr-2187, lire en ligne)
(en) McVean J, Forlenza GP, Beck RW et al., « Effect of tight glycemic control on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial », JAMA, vol. 329, no 12, , :980-99. (PMID36826834, PMCIDPMC9960023, DOI10.1001/jama.2023.2063, lire en ligne)
(en) Lundstrom T, Ryden L, « Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil », J Am Coll Cardiol, vol. 16, no 1, , p. 86–90. (PMID2358610, DOI10.1016/0735-1097(90)90461-w, lire en ligne)
(en) Gulamhusein S, Ko P, Carruthers SG et al., « Acceleration of the ventricular response during atrial fibrillation in the Wolff-Parkinson-White syndrome after verapamil », Circulation, vol. 65, no 2, , p. 348–54. (PMID7053894, DOI10.1161/01.cir.65.2.348, lire en ligne)
(en) Lundstrom T, Ryden L, « Ventricular rate control and exercise performance in chronic atrial fibrillation: effects of diltiazem and verapamil », J Am Coll Cardiol, vol. 16, no 1, , p. 86–90. (PMID2358610, DOI10.1016/0735-1097(90)90461-w, lire en ligne)
